{"id":"NCT00770913","sponsor":"Eisai Co., Ltd.","briefTitle":"Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis","officialTitle":"Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-10","primaryCompletion":"2009-11","completion":"2010-03","firstPosted":"2008-10-10","resultsPosted":"2012-04-13","lastUpdate":"2012-04-18"},"enrollment":337,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Reflux Esophagitis"],"interventions":[{"type":"DRUG","name":"E3810","otherNames":["Aciphex"]},{"type":"DRUG","name":"E3810","otherNames":["Aciphex"]},{"type":"DRUG","name":"E3810","otherNames":["Aciphex"]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.","primaryOutcome":{"measure":"Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)","timeFrame":"8 weeks","effectByArm":[{"arm":"E3810 20 mg Once Daily","deltaMin":58.8,"sd":null},{"arm":"E3810 10 mg Twice Daily","deltaMin":78.4,"sd":null},{"arm":"E3810 20 mg","deltaMin":77,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":54,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":112},"commonTop":["Nasopharyngitis","Blood thyroid stimulating hormone increased","Constipation","Upper respiratory tract inflammation","Diarrhoea"]}}